Compare GSK plc (GSK) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Vale SA — how do they compare? GSK plc trades at $52.4 (market cap $101.34B), while Vale SA trades at $14.3 (market cap $61.19B). The key difference: GSK plc is the larger of the two by market cap, and Vale SA pays the higher dividend (8.58%). Which is the better fit depends on your goals.
| GSK | VALE | |
|---|---|---|
Market Cap | $101.34B | $61.19B |
Sector | Health | Basic Materials |
52-Week High | $61.18 | $17.82 |
52-Week Low | $36.20 | $9.53 |
Enterprise Value | $121.95B | $78.11B |
Dividend Yield | 3.49% | 8.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
VALE trades at $14.59, up 2.89% in the last session, with a bearish technical signal and mixed earnings history. Recent quarters show volatility with one beat and two misses. The company maintains solid cash flow from operations at $8.8B in 2025, though net income margin has declined to 7.21%. News highlights include a $2.6B decarbonization investment plan (Reuters, 2026-06-15) and governance tensions with a board rejecting a chairman removal push (GuruFocus, 2026-06-22).
The outlook is cautious with analyst consensus at Buy (40.54%) but near-term risks from earnings volatility and debt levels. Upside exists if the company meets Q2 2026 EPS expectations of $0.46, supported by robust metals demand per CEO comments (Bloomberg, 2026-06-09). Key risks include profit margin pressure and geopolitical impacts on operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
